Eris Biotech recently launched!

Launch YC: Eris Biotech - Developing cancer drugs that target tumors without poisoning the rest of the body

"Hypoxia-activated prodrugs for the treatment of solid tumors"

Eris Biotech is developing hypoxia-activated prodrugs (HAPs) for the treatment of solid tumors.

Founded by Rachel Garlick & Evita Weagel

About Eris Biotech

The startup is developing innovative treatments to specifically target the tumor microenvironment, ensuring maximum effectiveness with minimal side effects. These cancer-fighting drugs only become active inside solid tumors. By delivering active drugs only to the tumor site, it localizes the effects of the drugs to the tumor and minimize systemic toxicity. Eris Biotech is not just developing medicine, they're crafting hope.

The Problem

Cancer therapies are terrible! It’s a race between who kills you first: the therapeutic or the cancer. Eris Biotech wants to help with that, starting with mesothelioma. Mesothelioma is a type of cancer that grows on the pleura, the thin layer surrounding the lungs, with a 5-year survival rate of <13%. Current mesothelioma treatments not only fall short in effectiveness but are also systemically toxic, and most patients diagnosed with mesothelioma will die within 14 months after diagnosis.

Eris Biotech's Solution

Eris Biotech develops drugs that only activate under low oxygen (hypoxic) environments. These drugs are referred to as hypoxia-activated prodrugs or HAPs. A low oxygen or hypoxic environment is a hallmark of the majority of solid tumors, including mesothelioma, and healthy tissues are usually not hypoxic. By delivering active drugs only to the tumor site, Eris Biotech can use more potent drugs without systemic toxicity in cancer therapeutics.

To develop their first HAP, Eris Biotech used AI drug discovery tools and AI-designed compounds from a library of over 2.6 million compounds. The startup's first HAP in development blocks the communication between the tumor and its surroundings. This lack of communication isolates tumors from essential resources, driving tumor death.

Image Credits: Eris Biotech

Learn more

🌐 Visit to learn more

🤝 Want to learn more about Eris Biotech's science and mission? Reach out to the founders!

👥 Follow Eris Biotech on

February 14, 2024
← Back to all posts  

Join Our Newsletter and Get the Latest
Posts to Your Inbox

No spam ever. Read our Privacy Policy
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.